WHANIN PHARM revenue for the last year amounted to 230.40 B KRW, the most of which — 176.81 B KRW — came from its highest performing source at the moment, Psychotropic Drug, the year earlier bringing 155.25 B KRW. The greatest contribution to the revenue figure was made by South Korea — last year it brought WHANIN PHARM 230.39 B KRW, and the year before that — 198.93 B KRW.